About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETED

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

A Non-Interventional Multinational Study to Assess PD-L1 Expression in Cytological Versus Histological Non-Small Cell or Small Cell Lung Cancer Specimens

NCT03092739•Hoffmann-La Roche

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Carcinoma, Non-Small-Cell LungCarcinoma, Small Cell

Interventions

PD-L1 Immunocytochemistry (ICC)

PD-L1 Immunohistochemistry (IHC)

Locations

8

Czechia

Locations (8)

Vseobecna fakultni nemocnice v Praze; I. klinika tuberkulozy a respiracnich nemoci

Prague, Czechia

Universitätsklinikum Göttingen, Institut für Pathologie

Göttingen, Germany

Instytut Gruźlicy i Chorób Płuc, I Klinika Chorób Płuc

Warsaw, Poland

Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Anatomía Patológica

A Coruña, LA Coruña, Spain

Hospital Universitario La Paz; Servicio de Anatomia Patologica

Madrid, Spain

HOSPITAL DE MADRID NORTE SANCHINARRO- C. INTEGRAL ONC. CLARA CAMPAL; Servicio Anatomia Patologica

Madrid, Spain

Key Dates

Start Date

May 3, 2017

Primary Completion Date

January 8, 2018

Completion Date

June 6, 2018

Last Updated

July 23, 2019

Related Studies

RECRUITINGPhase 2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

Carcinoma, Non-Small-Cell Lung

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798

Carcinoma, Non-Small-Cell Lung

RECRUITINGPhase 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310

Carcinoma, Non-Small-Cell Lung

RECRUITINGPhase 1

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923

Carcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma+3 more

RECRUITINGPhase 3

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566

Advanced Non-Small Cell Lung CancerNon-Small Cell Lung Cancer+4 more

RECRUITINGPhase 2

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076

Carcinoma, Non-Small-Cell Lung

View all related studies

Sponsors

Lead Sponsor

Hoffmann-La Roche

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 23, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions